Ameriprise
AXSM icon

Ameriprise’s Axsome Therapeutics AXSM Stock Holding History

Ameriprise’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$29.8M Buy
176,314
+76,398
+76% +$13.2M 0.01% 1157
2025
Q4 		$18.2M Sell
99,916
-8,320
-8% -$1.16M ﹤0.01% 1479
2025
Q3 		$13.1M Buy
108,236
+38,152
+54% +$4.3M ﹤0.01% 1708
2025
Q2 		$7.32M Buy
70,084
+54,068
+338% +$5.73M ﹤0.01% 2050
2025
Q1 		$1.87M Sell
16,016
-2,222
-12% -$253K ﹤0.01% 2938
2024
Q4 		$1.54M Sell
18,238
-179,697
-91% -$16.5M ﹤0.01% 3060
2024
Q3 		$17.8M Buy
197,935
+152,620
+337% +$13.3M ﹤0.01% 1402
2024
Q2 		$3.65M Buy
45,315
+32,728
+260% +$2.42M ﹤0.01% 2534
2024
Q1 		$1M Buy
12,587
+6,438
+105% +$540K ﹤0.01% 3163
2023
Q4 		$489K Sell
6,149
-22,993
-79% -$1.54M ﹤0.01% 3455
2023
Q3 		$2.04M Sell
29,142
-514
-2% -$38.4K ﹤0.01% 2805
2023
Q2 		$2.13M Buy
29,656
+22,565
+318% +$1.66M ﹤0.01% 2839
2023
Q1 		$437K Buy
7,091
+1,166
+20% +$76.6K ﹤0.01% 3478
2022
Q4 		$457K Buy
5,925
+10
+0.2% +$598 ﹤0.01% 3440
2022
Q3 		$265K Buy
+5,915
New +$296K ﹤0.01% 3618

Other funds holding AXSM

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ameriprise's AXSM Position: Q1 2026 in Review

Ameriprise increased its Axsome Therapeutics (AXSM) stake by 76% in Q1 2026, buying an estimated $13.2M and bringing the position to 176,314 shares worth $29.8M. The position accounts for 0.01% of the portfolio, ranked #1157.

Ameriprise first reported a position in AXSM in Q3 2022 and has held it in 15 quarters since. 409 funds tracked by Wall St. Rank hold AXSM as of Q1 2026.

  • Ameriprise held 176,314 shares of Axsome Therapeutics worth $29.8M as of Q1 2026.
  • Ameriprise bought 76,398 Axsome Therapeutics shares in Q1 2026, an estimated $13.2M.
  • Axsome Therapeutics made up 0.01% of Ameriprise's portfolio in Q1 2026, its #1157 holding.
  • Ameriprise first reported a position in Axsome Therapeutics in Q3 2022 and has held it in 15 quarters since.
  • 409 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q1 2026.

Based on Ameriprise's 13F filing for Q1 2026, filed 15 May 2026.